Here's why the Avita Medical share price is tumbling 20% today

Shares in the healthcare company are tanking today, despite no fresh news out since last week.

Key points
  • Avita Medical shares have copped a pounding today, down close to 20%
  • The dual-listed company released an update last Friday, but ASX investors seemed to be far more forgiving back then
  • It seems ASX investors might be following Avita's less-forgiving US investors today

It's been a fairly lacklustre start to the trading week for most ASX shares so far this Monday. At the time of writing, the All Ordinaries Index (ASX: XAO) has fallen by 0.21%. But let's talk about the plunging Avita Medical Inc. (ASX: AVH) share price.

Avita Medical shares are in freefall today. This ASX healthcare share has dropped by a precipitous 19.38% so far this Monday to $3.66 a share. That comes after Avita shares closed at $4.54 each last Friday.

It was even worse for Avita this morning too, with the shares hitting a low of $3.53 soon after market open. That was a drop of 22.25% at the time.

So what on earth is going on with Avita shares today that has this company losing so much value?

A man sits uncomfortably at his laptop computer in an outdoor location at a table with trees in the background as he clutches the back of his neck with a wincing look on his face.

Image source: Getty Images

Why has the Avita Medical share price lost 20% today?

Well, Avita is a bit of a unique case on the ASX. The company is actually a dual-listed share, with its other listing being on the United States NASDAQ exchange – Avita Medical Inc. (NASDAQ: RCEL).

Last Friday, Avita released some financial results and guidance to investors, covering the three months to 31 March 2023. These results revealed a 40% increase in revenue for the quarter to $10.6 million, as well as a rise in gross profit margins to 84%.

The company also announced a major change in its leadership team. Chief commercial officer Erin Liberto has resigned from the company, while Terry Bromley and Debbie Gardener have been promoted to senior vice president of global sales, and senior vice president of global marketing and strategy respectively.

ASX investors reacted negatively to this news on Friday's session, sending Avita shares down by 5.42%.

But Avita's American investors were far more savage on Friday night (our time). Over on the NASDAQ, the Avita share price tanked by a nasty 22.94%.

It seems Avita's ASX investors might be taking a lead from their American counterparts today in the wake of Friday's far more savage reaction. This could explain the doubling down of selling pressure that we seem to be witnessing on the ASX today.

But shareholders arguably don't have too much to complain about. Even after today's savage selling, the Avita share price on the ASX is still up a whopping 90% in 2023 so far:

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »